Abstract

Bruton's tyrosine kinase (BTK) is a crucial signaling protein that links B-cell antigen receptor signaling to the activation, proliferation, and survival of B-cells. The development of very specific small-molecule BTK inhibitors has made BTK an important therapeutic target in the treatment of B-cell malignancies and autoimmune diseases. Here, we discuss the role of BTK in BCR signaling and the current status of BTK inhibition in B-cell malignancies and autoimmunity.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call